About Us

About MAXIGHT Technology

Founded in Singapore in 2024, MAXIGHT Technology is a MedTech startup that focuses on technological innovation in the fields of myopia prevention and control and visual health display. Relying on its own original R&D strength, the company has pioneered distant imaging display devices and the D.I.T digital therapy that integrate extended reality, PBM and AI technologies. These devices can provide users with a distant imaging visual experience like that in an IMAX theater. By integrating cutting - edge PBM spectral technology, they can accurately act on the retina and mitochondria, significantly improving their functions and providing an innovative solution with great potential for myopia prevention and control.

Our Vision

With the vision of "Empower Clearer Vision", the company is committed to making the MAXIGHT distant imaging series of products not only an effective means to improve eyesight and prevent myopia, but also a next - generation eye – friendly display and smart learning devices to create a healthy and innovative education ecosystem. It aims to help children around the world stay away from myopia and enjoy a better visual life.

Milestones and Achievements

MAXIGHT Technology traces its roots to Shanghai Ruishi Health Technology, a leading brand in children’s eye health management in China. Since its inception, MAXIGHT has received unwavering support from Ruishi Technology. In 2023, we were honoured with the prestigious Corporate Challenge award by Johnson & Johnson at the Asia Pacific MedTech Forum for our outstanding contributions to myopia prevention.

In 2024, we joined Johnson & Johnson’s global innovation ecosystem, JLAB Singapore, and were invited to share our success story at the Asia Pacific MedTech Forum as a standout example of Chinese innovation expanding overseas.

Technologically, 2024 marked a significant milestone with the launch of our third-generation distant imaging display devices: the high-performance Vision Pro PBM and the world’s first portable Vision Smart children’s eye-care learning device. Collaborating with top-tier medical research institutions in China and planning local clinical studies, we are committed to advancing myopia control solutions.

Looking Ahead: 2025 and Beyond

As we step into 2025, MAXIGHT has forged partnerships with local digital marketing firms and optometry experts to establish robust offline and online distribution channels. Our goal is to deliver the latest products and professional services to both local and international markets, driving progress in myopia prevention and visual health.

Moving forward, we will deepen collaborations with hospitals and ophthalmologists to conduct extensive clinical research, unlocking the full potential of innovative myopia control technologies and reducing childhood myopia rates across the region.

About Our Parent Company: Ruishi Health Technology

Shanghai Ruishi Health Technology is a high-tech innovator specialising in digital medical solutions for children’s myopia management. With a portfolio of patented distant imaging and digital defocus technologies, Ruishi is recognised as a national-level "Specialised, Refined, Distinctive, and Innovative" enterprise in China.

Since its founding in 2020, Ruishi has rapidly emerged as a leader in children’s eye health, securing over RMB 200 million in investments from top-tier venture capital firms like BlueRun Ventures and Sinovation Ventures. In 2024, Ruishi established MAXIGHT as its overseas operations hub, beginning in Singapore and aiming to replicate its success on the global stage.